Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method

By Jelena Martinovic
June 20, 12:15 PM
Cannabinoids-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday that it has entered into a licensing agreement with Remidose Aerosols Inc. to acquire the exclusive rights for advanced cannabis products. Under the deal, current Remidose customers will be serviced through MediPharm starting August 2024, including Canadian direct-to-patient medical platforms and international medical distributors. MediPharm intends to utilize its existing GMP infrastructure, customer channels and wellness sales expertise to expand the customer base of these advanced products in Canada and internationally.

MEDIF

Read More
2 minute read

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

By Jelena Martinovic
March 27, 6:32 PM
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF

Read More
1 minute read

Cannabinoids & Autism Spectrum Disorder: This Baltimore Company Is On Track To Start Phase 2 Clinical Trial For New Treatment

By Jelena Martinovic
October 7, 11:27 AM
Cannabinoid-focused biopharmaceutical company Greater Cannabis Company, Inc. (OTC: GCAN) has submitted a clinical trial application to the Israel Ministry of Health for approval of Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy.

GCAN